Analyst Price Target is $20.00
▲ +502.41% Upside Potential
This price target is based on 0 analysts offering 12 month price targets for ESSA Pharma in the last 3 months. The average price target is $20.00, with a high forecast of $20.00 and a low forecast of $20.00. The average price target represents a 502.41% upside from the last price of $3.32.
Current Consensus is
The current consensus among 0 polled investment analysts is to n/a stock in ESSA Pharma. This rating has held steady since August 2022, when it changed from a Buy consensus rating.
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.